

Stanford



Radhika Kumari

Clinical Associate Professor, Medicine - Gastroenterology & Hepatology

CLINICAL OFFICES

- **Stanford Gastroenterology and Digestive Health Clinic**

420 Broadway St

Pav D 2nd Fl Pod 2 and 3

Redwood City, CA 94063

Tel (650) 498-7999

Fax (650) 724-9454

Bio

BIO

Dr Kumari's clinical interests lie in taking care of patients with Hepatitis C, cirrhosis and complications, liver cancer and management of post transplant patients. Her research interests are doing Translational research in Portal Hypertension and its complications.

CLINICAL FOCUS

- Gastroenterology
- Transplant Hepatology

ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Medicine - Gastroenterology & Hepatology

PROFESSIONAL EDUCATION

- Residency: St Louis University School of Medicine (2006) MO
- Internship: St Louis University School of Medicine (2004) MO
- Board Certification: Transplant Hepatology, American Board of Internal Medicine (2014)
- Board Certification: Gastroenterology, American Board of Internal Medicine (2011)
- Fellowship: Saint Louis University Division of Gastroenterology and Hepatology (2011) MO
- Fellowship: Saint Louis University Division of Gastroenterology and Hepatology (2007) MO
- Medical Education: Sri Venkates Medical College (2000) India

Publications

PUBLICATIONS

- **Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy.** *Hepatology communications* Alshuwaykh, O., Daugherty, T., Cheung, A., Goel, A., Dhanasekaran, R., Ghaziani, T. T., Ahmed, A., Dronamraju, D., Kumari, R., Kwong, A., Nguyen, M., Kim, W. R., Kwo, et al

2022

- **Predictors of Outcomes of Patients Referred to a Transplant Center for Urgent Liver Transplantation Evaluation.** *Hepatology communications*
Alshuwaykh, O., Kwong, A., Goel, A., Cheung, A., Dhanasekaran, R., Ahmed, A., Daugherty, T., Dronamraju, D., Kumari, R., Kim, W. R., Nguyen, M. H., Esquivel, C. O., Concepcion, et al
2021; 5 (3): 516-525
- **Trends in the Prevalence of Hepatitis C Virus Infection based on the Insurance Status in the United States from 2013 to 2018.** *Liver international : official journal of the International Association for the Study of the Liver*
Kim, D., Cholankeril, G., Dennis, B. B., Alshuwaykh, O., Kumari, R., Wong, R. J., Ahmed, A.
2021
- **Predictors of Outcomes of Patients Referred to a Transplant Center for Urgent Liver Transplantation Evaluation** *HEPATOLOGY COMMUNICATIONS*
Alshuwaykh, O., Kwong, A., Goel, A., Cheung, A., Dhanasekaran, R., Ahmed, A., Daugherty, T., Dronamraju, D., Kumari, R., Kim, W., Esquivel, C. O., Concepcion, W., Melcher, et al
2020
- **Strongyloides Superinfection After Liver Transplantation.** *Digestive diseases and sciences*
Ofosu, A., Higgins, J., Frye, J. S., Kumari, R., Barakat, M. T.
2020
- **THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B VIRUS INFECTION SUBJECTS NOT MEETING CRITERIA FOR ANTIVIRAL THERAPY**
Alshuwaykh, O., Goel, A., Daugherty, T., Cheung, A., Kim, W., Kwong, A. J., Ahmed, A., Ghaziani, T., Torok, N. J., Nguyen, M. H., Dronamraju, D., Dhanasekaran, R., Kumari, et al
WILEY.2020: 472A–473A
- **Clinical Response to Treatment for Acute Kidney Injury (AKI) in Patients With Cirrhosis**
John, N., Alshuwaykh, O., Goel, A., Ahmed, A., Cheung, A., Dronamraju, D., Kumari, R., Daugherty, T., Dhanasekaran, R., Kim, R. W., Nguyen, M. H., Kwo, P. Y.
LIPPINCOTT WILLIAMS & WILKINS.2020: S587–S588
- **Characterizing Ascites in Subjects With Nonhepatic Solid Tumors**
Alshuwaykh, O., Cheung, A., Goel, A., Dhanasekaran, R., Ahmed, A., Dronamraju, D., Daugherty, T., Kim, R. W., Kumari, R., Torok, N., Ghaziani, T., Kwo, P. Y.
LIPPINCOTT WILLIAMS & WILKINS.2020: S507
- **THE ROLE OF LOCOREGIONAL THERAPY (LRT), POST LRT IMAGING, AND EXPLANT PATHOLOGY AS PREDICTORS OF HEPATOCELLULAR CARCINOMA (HCC) RECURRENCE POST ORTHOTOPIC LIVER TRANSPLANT (OLT)**
Prabhakar, V., Dhanasekaran, R., Arjunan, V., Tulu, Z., Ahmed, A., Daugherty, T., Kumari, R., Patel, B., Kim, W., Goel, A., Esquivel, C. O., Concepcion, W., Melcher, et al
WILEY.2019: 691A–692A
- **Temporal Trends in Disease Presentation and Survival of Patients With Hepatocellular Carcinoma: A Real-World Experience From 1998 to 2015** *CANCER*
Kim, N. G., Nguyen, P. P., Dang, H., Kumari, R., Garcia, G., Esquivel, C. O., Nguyen, M. H.
2018; 124 (12): 2588–98
- **Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015.** *Cancer*
Kim, N. G., Nguyen, P. P., Dang, H. n., Kumari, R. n., Garcia, G. n., Esquivel, C. O., Nguyen, M. H.
2018
- **Optimizing the Nutritional Support of Adult Patients in the Setting of Cirrhosis.** *Nutrients*
Perumpail, B. J., Li, A. A., Cholankeril, G., Kumari, R., Ahmed, A.
2017; 9 (10)
- **Optimizing the Nutritional Support of Adult Patients in the Setting of Cirrhosis** *NUTRIENTS*
Perumpail, B. J., Li, A. A., Cholankeril, G., Kumari, R., Ahmed, A.
2017; 9 (10)
- **Increased Prevalence of Metabolic Risk Factors in Asian Americans With Hepatocellular Carcinoma.** *Journal of clinical gastroenterology*
Kutsenko, A., Ladenheim, M. R., Kim, N., Nguyen, P., Chen, V., Jayasekera, C., Yang, J. D., Kumari, R., Roberts, L., Nguyen, M. H.

2017; 51 (4): 384-390

- **Sofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center Experience.** *Journal of clinical and translational hepatology*
Aggarwal, A., Yoo, E. R., Perumpail, R. B., Cholankeril, G., Kumari, R., Daugherty, T. J., Lapasaran, A. S., Ahmed, A.
2017; 5 (1): 23-26
- **Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease.** *Medicine*
Chang, C. Y., Nguyen, P., Le, A., Zhao, C., Ahmed, A., Daugherty, T., Garcia, G., Lutchman, G., Kumari, R., Nguyen, M. H.
2017; 96 (6)
- **Sofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center Experience** *JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY*
Aggarwal, A., Yoo, E. R., Perumpail, R. B., Cholankeril, G., Kumari, R., Daugherty, T. J., Lapasaran, A. S., Ahmed, A.
2017; 5 (1): 23-26
- **Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1.** *Alimentary pharmacology & therapeutics*
Lutchman, G., Nguyen, N. H., Chang, C. Y., Ahmed, A., Daugherty, T., Garcia, G., Kumari, R., Gupta, S., Doshi, D., Nguyen, M. H.
2016; 44 (7): 738-746
- **Differences in Hepatocellular Carcinoma Incidence and Survival Rates among Asian Mono-Ethnicities**
Cholankeril, G., Perumpail, R. B., Hu, M., Pham, E. A., Kumari, R., Gish, R., So, S. K., Dhanasekaran, R., Ahmed, A.
WILEY.2016: 860A
- **Outcomes in Patients with Severe Hepatic Encephalopathy and MELD 30 to 34 Justifies Exception to MELD 35 and Higher**
Cholankeril, G., Perumpail, R. B., Aggarwal, A., Hu, M., Jayasekera, C. R., Kumari, R., Holt, E. W., Harrison, S. A., Wong, R. J., Ahmed, A.
WILEY.2016: 709A
- **Fulminant Hepatic Failure from Diff use Infiltration by Metastatic Melanoma**
Holmes, I., Kumari, R.
NATURE PUBLISHING GROUP.2016: S949-S950
- **The Effect of Gastric Acid Suppression on Ledipasivir-Sofosbuvir Effectiveness in Chronic Hepatitis C Infection**
Swanner, A., Kumari, R., Garcia, G., Daugherty, T., Nguyen, M. H., Ahmed, A., Kim, W., Lutchman, G. A.
WILEY.2016: 947A
- **Advances in cirrhosis: Optimizing the management of hepatic encephalopathy.** *World journal of hepatology*
Liu, A., Perumpail, R. B., Kumari, R., Younossi, Z. M., Wong, R. J., Ahmed, A.
2015; 7 (29): 2871-2879
- **Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis** *TRANSPLANT INFECTIOUS DISEASE*
Perumpail, R. B., Wong, R. J., Ha, L. D., Pham, E. A., Wang, U., Luong, H., Kumari, R., Daugherty, T. J., Higgins, J. P., Younossi, Z. M., Kim, W. R., Glenn, J. S., Ahmed, et al
2015; 17 (2): 275-278
- **Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1.** *Expert opinion on pharmacotherapy*
Kumari, R., Nguyen, M. H.
2015; 16 (5): 739-748
- **Coffee: a panacea or snake oil for the liver?** *Clinical gastroenterology and hepatology*
Kumari, R., Kim, W. R.
2014; 12 (9): 1569-1571
- **Antibiotic Prophylaxis among Hospitalized End-Stage Liver Disease Patients with Model for End-Stage Liver Disease Score above Thirty: How Do the Physicians in the United States Practice?**
Mathur, A., Puri, N., Kumari, R.
NATURE PUBLISHING GROUP.2013: S153